Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Completed · Phase 3 · Has a placebo group

Conditions studied: Lung Cancer - Non Small Cell Squamous

In brief

The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.

Key facts

Study ID
NCT01285609
Run by
Bristol-Myers Squibb
People needed
1289
Starts
2011-01-16
Expected to finish
2017-08-22
Last updated by the study team
2020-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.